Navigation Links
New study of Concerta showed significant improvement of ADHD symptom management in adults
Date:10/26/2007

Boston, Mass., Friday Oct. 26, 2007 11:00AM Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA OROS methylphenidate HCl Extended-release Tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented today at a major psychiatric medical meeting.

Pharmacological treatment of children and adolescents with ADHD is clearly established but relatively less is known about the treatment of adults with ADHD, notes the studys medical director, Sally Berry, M.D., PhD., of Johnson & Johnson Pharmaceutical Research and Development, LLC. Were encouraged that the CONCERTA findings presented today -- in which CONCERTA significantly improved ADHD symptom management in adults -- can benefit the growing body of knowledge in this important therapeutic area.

The data presented today are part of a Supplemental New Drug Application (sNDA) submitted in August 2007 to the Food and Drug Administration for use of CONCERTA to treat adults with ADHD. CONCERTA is already approved for the treatment of ADHD in children and adolescents ages six to 17.

About the Study

In the study presented today, efficacy was measured as a change in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score. The results showed that CONCERTA achieved a significantly superior reduction in AISRS total score compared to placebo (p=0.012) (mean change was -10.6 1.09 for the CONCERTA group vs. -6.8 1.06 for the placebo group.

In addition, CONCERTA was significantly superior compared to placebo for the key secondary efficacy variables: change in Clinical Global Impression-Improvement (CGI-I) rating (p=0.008); change in Conners Adult ADHD Rating Scale-Self Report (CAARS-S:S) total score (p=0.029) and change in percent of subjects meeting pre-defined Responder criteria (p=0.009).

In the study, 229 patients with ADHD aged 18-65 years were randomized to receive CONCERTA 36-108 mg/day or placebo, for seven weeks. The final analysis set contained data from 226 patients . Patients in the CONCERTA group received a starting dose of 36 mg/day and the dose was increased in 18 mg increments every seven days (2 days) for up to five weeks until response (AISRS scores decreased by 30% and CGI-I rating of 1 very much or 2 much improved) was achieved or titration to the maximum dose of 108 mg. The dose could be reduced one time during the study for tolerability reasons. The mean final dose was 67.7 mg/day.

Adverse events were reported by 93 (84.5%) of patients in the CONCERTA group compared with 74 (63.8%) in the placebo group. The most commonly reported adverse events with CONCERTA included decreased appetite (25.5%), headache (25.5%), dry mouth (20%), anxiety (16.4%), nausea (12.7%), increased blood pressure (10%), insomnia (9.1%), initial insomnia (7.3%), increased heart rate (7.3%), bruxism (6.4%), irritability (6.4%) and muscle tightness (6.4%). There were no serious treatment emergent adverse events reported and 16 (14.5%) and 6 (5.2%) subjects in the CONCERTA and placebo groups, respectively, discontinued due to adverse events.

Todays data presentation included interim results from a long-term, open-label safety study. A similar dose titration protocol was used as in the double-blind study during the first weeks of the study after which the dose was flexible within the range of 36 to 108 mg. Interim results show that CONCERTA was well tolerated in an adult population with ADHD in a dose range from 36mg to 108 mg per day for up to six months.


'/>"/>

Contact: Tricia Geoghegan
tgeogheg@janus.jnj.com
609-462-8764
Golin/Harris International
Source:Eurekalert

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance ... With the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more ... 2012, the Biggert-Waters Act was enacted to reflect the actual risk in flood ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, ... to families and business owners in and around Lackawanna County, is joining Meals ... in the area. , Meals on Wheels of NEPA provides hand-delivered and nutritious ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is proud to report ... 2017. Each year, research and information firm, Castle Connolly, releases their list of the ... this marks the 3rd time that Dr. Canales has been recognized by ...
Breaking Medicine News(10 mins):
(Date:5/29/2017)... 2017  Cellect Biotechnology Ltd. (NASDAQ: APOP ... the functional selection of stem cells, today provided a ... quarter ended March 31 st , 2017. ... the first quarter of 2017," said Dr. Shai Yarkoni, ... the treatment of the first blood cancer patient in ...
(Date:5/24/2017)... 2017  ivWatch LLC today announced the launch ... to enable seamless integration of ivWatch,s groundbreaking IV ... pumps and other devices. By integrating ivWatch technology ... help health care customers deliver a higher level ... IV therapy. "The ivWatch OEM Board ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology: